Neoadjuvant therapy for gastroesophageal adenocarcinoma

Table 2 Neoadjuvant chemoradiotherapy schedule offered in the treatment of resectable gastroesophageal junction and lower esophagus adenocarcinomas

Trials	Patients (n)	Pathology	CT-RT	5-yr OS rate (%)
Walsh 1996	CT-RT = 58 S = 55	ADK (100%)	CDDP-5FU 40 Gy	CT-RT 32% S 6% (3-yr OS) (P = 0.01)
Urba 2001	CT-RT = 50 S = 50	ADK (75%) SCC	CDDP-VLB-5FU 45 Gy	CT-RT 30% S 16% (3-yr S) (P = 0.15)
Burmeister 2005	CT-RT = 128 S = 128	ADK (62%) SCC	CDDP-5FU 35 Gy	CT-RT 22 mo S 19 mo (P = 0.38)
Tepper 2008	CT-RT = 30 S = 26	ADK (75%) SCC	CDDP-5FU 50.4 Gy	CT-RT 39% S 16% (P < 0.008)
CROSS 2010	CT-RT = 180 S = 188	ADK (75%) SCC	Paclitaxel-carboplatin 41.4 Gy	CT-RT 47% S 34% (P = 0.03)

CT-RT: Chemoradiotherapy; OS: Overall survival; S: Surgery; ADK: Adenocarcinoma; SCC: Squamous cell carcinoma; VLB: Vinblastin.